Does testosterone cypionate's half-life mean weekly injections are enough?

What did @stevenfnp83 actually say?

The creator, who identifies as an NP offering coaching calls, argued that daily testosterone cypionate injections are "usually overkill" because the drug has a half-life of about seven days, meaning levels taper gradually rather than crashing overnight. He suggested that "two to three times a week is usually enough to feel consistent" for most men on TRT. He was careful to say he is not prescribing anything, though he did pitch paid one-on-one coaching at the end.

The core claim is straightforward: the pharmacokinetics of testosterone cypionate support less frequent dosing than daily microdosing protocols, and simpler schedules can produce stable levels. That is a reasonable starting point, but the framing glosses over some important nuance that matters clinically.

Does the science back this up?

Mostly, yes, with caveats. The half-life figure is in the right ballpark, and the general logic holds, but individual variability is larger than the video implies.

Testosterone cypionate's half-life is commonly cited at approximately 8 days, not exactly 7, though the range in the literature runs from 7 to 8 days depending on the source (Bhasin et al., 2010, New England Journal of Medicine). This distinction matters less than it might seem, because the functional takeaway is the same: serum levels do not collapse between weekly or twice-weekly injections the way short-ester compounds would.

Research supports less frequent dosing as clinically viable. A study by Snyder et al. (2016, NEJM) used weekly intramuscular testosterone injections in older men and achieved stable, therapeutic serum levels. Multiple clinical guidelines, including those from the Endocrine Society, list once-weekly or twice-weekly injections as standard protocols. So the claim that twice or three times weekly is sufficient for most men is consistent with how regulated TRT is actually practiced.

Where the science gets complicated is in the word "most." Some men, particularly those who are sensitive to hormonal fluctuations, do report mood or energy variability with weekly dosing that resolves with more frequent smaller doses. That is not well-studied in large randomized trials, but it is a real clinical observation.

What did they get wrong (or right)?

Credit where it is due: the basic pharmacology is correct. Testosterone cypionate is a long-ester compound and twice-weekly injections are a clinically established standard, not some fringe simplification.

What the video gets wrong, or at least undersells, is the individual variability piece. The creator frames daily microdosing as essentially unnecessary for most men without acknowledging that some patients genuinely stabilize better on more frequent dosing. A 2021 paper by Ramasamy et al. (Translational Andrology and Urology) noted that injection frequency affects both trough and peak levels, and some men are more symptomatic at troughs than others.

The creator also conflates "stable levels" with "optimal outcomes." Serum testosterone being within range does not automatically mean a patient feels well. Estradiol conversion, SHBG levels, and individual receptor sensitivity all interact with how a man feels on any given schedule. None of that is mentioned.

Finally, offering paid coaching on injection scheduling while holding an NP credential sits in a regulatory gray zone. He disclaims prescribing, which is appropriate, but scheduling advice for a controlled substance protocol from a coach, not a treating provider, carries real liability and patient safety concerns that a 90-second TikTok cannot adequately contextualize.

What should you actually know?

If you are on TRT, your injection schedule should be set by the clinician managing your bloodwork, not a coaching call or a TikTok video. That said, the creator is not wrong that daily injections are not a universal requirement.

Here is what the evidence actually supports: twice-weekly subcutaneous or intramuscular testosterone cypionate injections are a well-validated protocol for most men with hypogonadism. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) recommend individualized dosing with periodic serum monitoring, not a one-size-fits-all frequency.

Daily subcutaneous microdosing has grown in popularity partly because it mimics a more physiologic release pattern and can reduce peak-to-trough swings. Some compounding pharmacies promote it, and some clinicians prefer it for patients with estradiol sensitivity. It is not overkill for everyone, even if it may be unnecessary for many.

The bottom line: frequency should be driven by your lab values, symptoms, and your provider's clinical judgment. Anyone selling a coaching call as a substitute for that process is offering something that belongs in a different category than medical care.